sop pharmaceutical industries empri 2005 12
TRANSCRIPT
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
1/61
Standard Operating Proceduresfor Pharmaceutical Industries
inal ReportDecember 2 5
nvironmental Managementand
Pol Research Institute
1
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
2/61
TABLE OF CONTENTS
ITEM CHAPTER PAGE NUMBER
1 INTRODUCTION ----- 11.1 Background ----- 1
1.2 Gist Of Environmental Acts, Rules And Notifications ----- 1
2 LEGAL AND REGULATORY FRAMEWORK ----- 22.1 Fundamental Rights And Duties Of A Citizen ----- 2
2.2 State Policy ----- 2
2.3 Legislative Authority ----- 2
2.4 Relevant Legislations ----- 3
2.4.1 Environment Protection Act 1986. ----- 3
2.4.2 The Water (Prevention And Control Of Pollution) Act, 1974
And Rules----- 3
2.4.3 The Water (Prevention And Control Of Pollution) Cess Act,
1977 And Rules
----- 4
2.4.4 The Air (Prevention And Control Of Pollution) Act, 1981 And
Rules----- 4
2.4.5 The Environment Impact Assessment Notification 1994 &
1997----- 4
2.4.6 The Noise Pollution (Regulation And Control) Rules, 2000 ----- 4
2.4.7 The Hazardous Waste (Management & Handling Rules), 2000 ----- 4
2.4.8 The Manufacture, Storage and Import of Hazardous Chemical
Rules, 1989----- 5
2.4.9 Rules for the Manufacture, Use, Import, Export and Storage
of Hazardous Micro organism/ Genetically engineered
Organisms or Cells, 1989
----- 5
2.4.10 The Chemical accidents (Emergency planning, Preparedness
and Response) Rules,1996----- 5
2.4.11 Forest Conservation Act 1980. ----- 6
2.4.12 The Drugs and Cosmetics Act, 1940 and Rules, 1945 ----- 6
2.4.13 The Drugs and Magic Remedies (Objectionable
Advertisements) Act, 1954----- 6
2.4.14 The Drugs Prices (Control) Order, 1995 ----- 6
2.5 Relevant Policies ----- 6
2.5.1 The National Forest Policy ----- 7
2.5.2 The National Environmental Policy ----- 8
2.5.3 The National Industrial Policy-----
9
2.5.4 Draft National Rehabilitation & Resettlement Policy ----- 10
2.5.5 The Pharma Policy 2002: The Positives and Negatives ----- 10
2.6 Regulatory Concerns on Nutraceuticals ----- 11
2.6.1 Mashelkar Committee Recommendations ----- 11
2.7 Relevant Institutions ----- 12
2.7.1 Ministry Of Environment And Forest, Government Of India ----- 12
2.7.2 Department Of Ecology And Environment, Government Of
Karnataka----- 12
2.7.3 Karnataka State Pollution Control Board ----- 12
2.8 Guidelines for setting up of Pharmaceutical Industries from
Karnataka State Pollution Control Board
12
3 RESPONSIBILITIES OF THE PHARMACEUTICAL AUTHORITIES ----- 15
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
3/61
ITEM CHAPTER PAGE NUMBER
3.1 Approvals ----- 15
3.2 Responsibilities ----- 15
4 WATER AND AIR (PREVENTION & CONTROL OF POLLUTIONACTS
----- 16
4.1 Consent Procedure ----- 165 WATER (PREVENTION & CONTROL OF POLLUTION) CESS
ACT----- 17
6 ENVIRONMENTAL IMPACT ASSESSMENTNOTIFICATION ----- 18
7 ENVIRONMENTAL STATEMENT PROCEDURES ----- 20
7.1 Contents Of Environmental Statement ----- 20
8 ENVIRONMENTAL AUDITING ----- 218.1 Features Of A Good Environmental Audit ----- 21
8.2 Audit Procedure ----- 22
9 ENVIRONMENTAL PERFORMANCE VERIFICATION EXERCISE ----- 2310 TYPES, SOURCES ANDNATURE OF POLLUTION FROM
PHARMACEUTICAL INDUSTRY
----- 24
10.1 Introduction ----- 24
10.2 Pharmaceutical Manufacturing Process ---- 24
10.3 Composition Of Pharmaceutical Products ----- 26
10.4 Composition Of Pharmaceutical Process Wastes ----- 27
10.5 Treatment Control Technologies ----- 28
10.5.1 Physical Treatment Process ----- 29
10.5.2 Chemical Treatment Process ----- 29
10.5.3 Biological Process ----- 29
10.5.4 Thermal Destruction Process ----- 30
10.5.5 Fixation And Stabilization Process ----- 3010.6 Pollution Prevention: Best Demonstrated Practices ----- 30
10.6.1 Source Reduction ----- 30
10.6.2 Material Substitution ----- 31
10.6.3 Process Modulation ----- 31
10.6.4 Good Operating Practices ----- 31
10.6.5 Recovery and Recycle ----- 33
10.6.6 Solvent Waste Recycling ----- 33
10.6.7 Waste Exchanges ----- 33
10.7 Summary ----- 34
11 CHARTER ON CORPORATE RESPONSIBILITY FOR
ENVIRONMENTAL PROTECTION (CREP)----- 35
12 EROS PHARMA A CASE STUDY ----- 36
12.1 Objectives of the project work ----- 36
12.2 Identification Of Various Wastestreams And Their
Characterization----- 36
12.3 Evaluation Of ETP ----- 37
12.4 Recommendations ----- 38
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
4/61
1
1 INTRODUCTION
1.1 BACKGROUND
The Pharmaceutical (Bulk & Formulation) industry in Karnataka is
one of the major sectors of the state. The processes in the pharmaindustries vary from company to company making the unit specific
industry disastrous to the environment if proper care is not taken. Some of
the environmental hazards include:
The diverse manufacturing process, reactions and hazardous materials
produces a wide range of chemical and biological waste.
The waste from purifying and packaging drug products.
Though the pharmaceutical owners, regulators and auditors have been addressing the
issues of environmental safeguards, it has been noticed that most to times they have to grope
through various acts, rules, documents to understand the various details of environmental
compliances. Thus, it was felt necessary to bring out a booklet that gives all the relevantinformation for the Pharma sector.
Presently, as per Rule 14 of the Environment Protection Rules, 1986, it is mandatory for
persons carrying out an industry or operation or process which require consent under Water Act,
1974 or Air Act, 1981 or authorization under the Hazardous Waste Rules, 1989, to submit every
year an Environmental Statement to the concerned State Pollution Control Board. However, the
existing mechanism does not provide for rigorous analysis of Environmental Statement by the
industries. Hence, it was felt that an effective institutional arrangement for implementing the
Environmental Audit is necessary.
1.2 GIST OF ENVIRONMENTALACTS,RULES AND NOTIFICATIONS
Pharmaceutical Industry is regulated by various legislations related to manufacturing andenvironment.
Environmental Legislations:
1. The Water (Prevention and Control of Pollution) Act, 1974 and Rules
2. The Water (Prevention and Control of Pollution) Cess Act, 1977 and
Rules
3. The Air (Prevention and Control of Pollution) Act, 1981 and Rules
4. Relevant provisions under Environmental Protection Act and Rules, 1986
The Environment Impact Assessment Notification 1994 & 1997
The Noise Pollution (Regulation and Control) Rules, 2000
The Municipal Solid Waste (Management & Handling Rules), 2000 Hazardous waste (management and Handling) Rules 1989
The manufacture, Storage and Import of Hazardous Chemical Rules, 1989
The Rules for the Manufacture, use, Import, Export and storage of Hazardous Micro-
organisms/Genetically Engineered Organisms or cells, 1989.
The Chemical accidents (Emergency planning, preparedness and Response) Rules, 1996
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
5/61
Standard Operating Procedure for Pharmaceutical Industry
2
2 LEGAL AND REGULATORY FRAMEWORK
To put the whole regulatory framework of India in perspective, a gist of constitutional
provisions that relate to the environment is given below.
2.1 FUNDAMENTALRIGHTS AND DUTIES OF A CITIZEN
1. Under the Indian Constitution, Part III [Fundamental Rights]
Article 21 states the fundamental right of protection of life and
personal liberty of an individual, No person shall be deprived of
his life or personal liberty except according to procedure
established by law. It should be noted that though this Article
does not explicitly mention the term environment, it is a
fundamental norm recognized by the court that every person
enjoys the right to a wholesome environment, which is a facet of right
to life under the above-mentioned Article.
2. Part IV A [Fundamental Duties] Article 51 A (g) states that It shall
be the duty of every citizen of India to protect and improve the naturalenvironment including forests, lakes, rivers and wildlife and to have
compassion for living creatures. This Article was inserted by the Constitutional (42nd
Amendment) Act, 1976.
2.2 STATE POLICY
The States responsibility has been laid down in the Part IV Directive Principle of
State Policy of the Constitution. The Article 48 A concerns the Environmental responsibility
of the State and was inserted by the Constitutional (42ndAmendment) Act, 1976. The Article
states that The State shall endeavour to protect and improve the environment and to safe guard
the forests and wild life of the country.
2.3 LEGISLATIVE AUTHORITY
The Part XI of Constitution states the relationship between the Union and the States for
sharing the legislative and administrative powers. Under this Part, the Article 245 of the
Constitution gives the extent of the laws made by the Parliament and the State Legislatures. The
Parliament has the power to legislate for the whole country while the State legislatures are
empowered to make laws for their respective states. The Article 246 of the Part XI of
Constitution divides the areas of legislation (subject wise) between the Union [List 1 or Union
List in 7thSchedule, 97 subjects], State Legislatures [List II or State List in 7thSchedule, 66
subjects] and both Parliament and State Legislatures [List III or Concurrent List in 7thSchedule,
52 subjects]. The subjects related to environment in the 7
th
Schedule under the three lists aresummarized below:
LIST
NO.
NAME SUBJECT NO. IN
LIST
SUBJECT
I Union 52 Industries
List 53 Regulation and development of oil fields and mineral oil
resources
54 Regulation of mines and mineral development
55 Regulation and development of Inter-State rivers and river
valleys
56 Fishing and fisheries beyond territorial waters
II State 6 Public health and sanitationList 14 Agriculture, protection against pest and prevention of plant
diseases
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
6/61
Standard Operating Procedure for Pharmaceutical Industry
3
LIST
NO.
NAME SUBJECT NO. IN
LIST
SUBJECT
18 Land, colonization, etc.
21 Fisheries
23 Regulation of mines and mineral development subject to the
provision of List I
24 Industries subject to the provision of List IIII Concurren
t
17 A Forests
List 17 B Protection of wild animals and birds
20 Economic and social planning
20 A Population control and family planning
The Parliament has powers to legislate on subjects not covered by the three Lists [Article
248].
The Parliament is also empowered to legislate in the national interest on matters
enumerated in the State List [Article 249].
In event of a conflict between the Central law and State law on a concurrent subject the
former prevails [Article 254 (1)].
In case of a State law passed subsequent to the Central law, the State law shall prevail in
that State only if it has received Presidential Assent under Article 254 (2) of Part XI of
Constitution.
From an environmental standpoint, the allocation of legislative authority is an important
one as some environmental problems such as sanitation and waste disposal are best tackled at
local level, while others like water pollution and wildlife protection are better regulated by
uniform national laws.
2.4 RELEVANT LEGISLATIONS
As stated earlier, the working environment within the pharma are regulated by the
Pharmaceutical legislations while the environment (air & water emissions, noise, waste) outside
the pharma are governed by environmental legislations.
2.4.1 Environment Protection Act 1986
An Act to provide for the protection and improvement of
environment and for the matter connected therewith. It is an
Umbrella Act covering all the activities leading to any environmental
impact including water, air and land. It confers powers to take all
such measures as it deems necessary or expedient for the purpose ofprotecting and improving the quality of the environment and
preventing, controlling and abating environmental pollution.
2.4.2 The Water (Prevention and Control of Pollution) Act, 1974 and Rules
The water (Prevention and Control of Pollution) Act, 1974, is an Act to provide for
prevention and control of water pollution and maintaining or restoring of wholesomeness of
water. The discharge of any trade effluent or sewage shall be regulated as per the consent of the
state Board. Such discharge has to meet the standards prescribed by the State Board.
Section 23:Empowers the Board Officials to inspect the industry, effluent treatment
plant and sewage treatment plant etc. Also empowers to seize documents, register, record or
other material object for the purpose of establishing evidence of the commission of an offence
punishable under this Act.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
7/61
Standard Operating Procedure for Pharmaceutical Industry
4
Section 24:Prohibits the pollution of stream or well or sewer or on
land by disposal of pollution matter etc., or no person shall knowing cause or
permit any poisonous, noxious or polluting matter into any stream or well or
sewer or on land.
2.4.3 The Water (Prevention and Control of Pollution) Cess Act, 1977 and Rules
The purpose of Water (Prevention & Control of Pollution) Cess Act is levy and collectcess on water consumed by 16 categories of industries specified in the act and also by local
bodies with a view to augment the resources of the Central and State Pollution Control Boards.
Water cess is levied based on the water consumed for domestic and specified industry.
2.4.4 The Air (Prevention and Control of Pollution) Act, 1981 and Rules
The Air (Prevention and Control of Pollution) Act, 1981, has (14 of
1981), is a specialized legislative measures, meant to tackle one facet of
environmental pollution. Its main objectives are the following:-
a) to provide for the prevention, control and abatement of air pollution;
b) to provide for the establishment of Central and State Boards, with a
view to implement the aforesaid purpose;
c) to provide for conferring on such Boards, the powers and assigning to
such Boards and functions relating thereto; and
d) for matters connected therewith.
2.4.5 The Environment Impact Assessment Notification 1994 & 1997
The Bulk Drugs and Pharmaceutical Industry require environmental clearance from the
Central Government. The Central and/or the State Government, with the following objectives
for environment clearance of polluting or degrading development activities:
- Optimal utilization of finite natural resources through use of better technologies and
management packages.- Incorporating suitable remedial measures at the project formulation stage.
2.4.6 The Noise Pollution (Regulation and Control) Rules, 2000
The State Government shall categorize the area into industrial,
commercial, residential or silence area/zones for the purpose of
implementation of noise, standards for different area. The ambient air quality
standards in respect of noise for different areas/zones shall be such as specified in
the Schedule annexed to these rules.
The noise levels in any area/zone shall not exceed the ambient air quality standards in
respect of noise as specified in the Schedule.The authority shall be responsible for the enforcement of noise pollution control
measures and the due compliance of the ambient air quality standards in respect of noise.
2.4.7 Hazardous Waste (Management and Handling) Rules 1989
These rules are applicable for hazardous wastes specified in Schedule and do not apply
to wastewater and air emissions covered under Air and Water Acts, and also radio-active wastes
and wastes arising out of ship operations beyond 5 Kms distance in Sea. Some of the
responsibilities of the industry include:
a) The Occupier and the Operator of a facility shall be responsible for proper collection,
reception, treatment, storage & disposal of hazardous waste listed in Schedule-1, 2 & 3.
b) It shall be the responsibility of the Occupier and the Operator of a facility to take allsteps to ensure that the wastes listed in Schedule-I, 2 & 3 are properly handled and
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
8/61
Standard Operating Procedure for Pharmaceutical Industry
5
disposed off without any adverse effect to the environment.
c) The Operator of a facility to take adequate steps while handling hazardous waste to:
i contain contaminants & prevent accident and limit their consequences on human and
the environment, and
ii provide persons working on the site with information, training and equipment
necessary to ensure their safety.2.4.8 The Manufacture, Storage and Import of Hazardous Chemical Rules, 1989
(1) These rules shall apply to,-
a) an industrial activity in which a hazardous chemical is or may be involved (part I of
Schedule I) and
b) isolated storage of a hazardous chemical in a quantity equal to more than the threshold
quantity (Schedule 2, in column 3)
(2) An occupier who has control of an industrial activity in terms of sub-rule (1) shall provide
evidence to show that he has,-
a) identified the major accident hazards; and
b) taken adequate steps to-
i. prevent such major accidents and to limit their consequences to persons and theenvironment;
ii. provide to the persons working on the site with the information, training and
equipment including antidotes necessary to ensure their safety.
2.4.9 The Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Micro-
organisms / Genetically Engineered Organisms or Cells, 1989.
These rules are applicable to the manufacture, import and storage of
micro-organisms and gene-technological products. These rules shall apply to
genetically engineered organisms/micro-organisms and cells and
correspondingly to any substances and products and food and stuff, etc., of
which such cells, organisms or tissues thereof form part.These rules shall also apply to new gene-technologies apart from those referred to in
clauses (ii) and (iv) of rule 3 and these rules shall apply to organisms/micro-organisms and cells
generated by the utilization of such other gene technologies and to substances and products of
which such organisms and cells form part.
2.4.10 The Chemical accidents (Emergency planning, Preparedness and Response) Rules,
1996
1. The Central Crisis Group shall be the apex body to deal with major chemical accidents
and to provide expert guidance for handling major chemical accidents.
2. Without prejudice to the functions specified under sub-rule (1), the central Crisis Groupshall,-
a) continuously monitor the post-accident situation arising out of a major chemical
accident and suggest measures for prevention and to check recurrence of such
accidents;
b) conduct post-accident analysis of such major chemical accidents and evaluate
responses;
c) publish a statewise list of experts and officials who are concerned with the handling
of chemical accidents;
d) render, in the event of a chemical accident in a state, all financial and infrastructural
help as may be necessary.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
9/61
Standard Operating Procedure for Pharmaceutical Industry
6
2.4.11 The Forest (Conservation) Act, 1980
This act was enacted to provide for the conservation of forests and for ancillary matters
connected with it. The act sets restriction on the dereservation of forests or use of forest land for
non-forest purpose for the State Government or other authority except with the
prior approval of the Central Government, for
i. To de-reserve any reserved forest;
ii. Use forest land for any non-forest purpose;
iii. Any forest land cleared of trees which have grown naturally in that land or portion, for
the purpose of using it for reafforestation.
2.4.12 The Drugs and Cosmetics Act, 1940 and Rules, 1945
Drugs and Cosmetics Act, 1940 is enacted to regulate the import, manufacture,
distribution and sale of drugs and cosmetics with the main object being the ensurance of
availability of standard quality drugs and cosmetics to the consumer and to prevent substandard
of medical treatment. In order to achieve the objects of the Act, drug is defined
comprehensively to include substances which are not only medicines but also substancesintended to be used for or in the treatment of diseases of human beings or animals. Also, the
legislative designedly extended the definition of drug so as to take in substances which are
necessary aids for treating surgical or other cases. The section 18 prohibits the manufacture for
sale, sale and distribution of adulterated, substandard and spurious drugs and cosmetics and the
manufacture for sale, sale and distribution of drugs or cosmetics except and in accordance with
conditions of licenses. Similar prohibitions are provided in respect of import of drugs and
Ayurvedic drugs. The amendments to the Drugs and Cosmetics Rules, 1945 was made by the
Central Government and now called the Drugs and Cosmetics (1stAmendment) Rules, 1998.
2.4.13 The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954
The main object and purpose of the Act is to prevent people from self-medication with
regard to various diseases as self medication in respect of diseases of serious nature has a
deleterious effect on the health of the Community and is likely to affect well being of the
people. The Act, has thus, been enacted with a view to control the advertisement of drugs in
respect of certain cases and to prohibit the advertisement for certain purposes of remedies
alleged to possess magic qualities.
2.4.14 The Drugs Prices (Control) Order, 1995
Drugs (Prices Control) Order, 1995 has been issued by the Central Government in
exercise of the powers under Section 3 of the Essential Commodities Act, 1955. The object of
the order is ensure availability of drugs at reasonable price, to prevent monopoly situation and togive effect to the New Drug Policy 1994.
2.5 RELEVANT POLICIES
The following list of the policies related to environment and pharma have been formed
since 1894:
1. Industrial Policy Resolution, 1948
2. National Forest Policy, 1894, 1952, 19883. Industrial Policy, 1956
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
10/61
Standard Operating Procedure for Pharmaceutical Industry
7
4. Industrial Policy Resolution, 1948
5. The Industrial Policy, 1991
6. The Policy Statement for Abatement of Pollution, 1992
7. The Export-Import Policy, 1997
8. National Health Policy, 2002
9. Pharma Policy, 2002
It is evident that the Policies being pursued presently have been evolved with experience
and with the considerations of various national and international developments and the country's
requirements for development. The Policies outline the guiding principles for the various
developmental and industrial activities. In addition to the National Policies some of the
pharmaceutical companies have formulated their own policies.
2.5.1 The National Forest Policy
The concern for the conservation and management of the forest wealth in the country is
almost 150 years old and the first effort on this account was made in the year 1855 with the
issuance of the 'Charter of Indian Forestry' and then the first Forest Policy in 1894. The firstForest Policy of the independent country was formulated as the National Forest Policy, 1952.
The National Forest Policy, 1988 was formulated and issued on 7 thDecember, 1988. This
Policy laid stress on the following.
1. Maintenance of environmental stability through preservation and, if necessary,
restoration of ecological balance that had been adversely affected by serious depletion of
the forests in the country.
2. Conserving the natural heritage of the country by preserving the remaining natural
forests having a vast variety of flora and fauna, which represent the remarkable
biological diversity and genetic resources of the country.
3. Checking soil erosion and denudation in the catchment areas of rivers, lakes,reservoirs, etc. in the interest of soil and water conservation, for mitigating floods and
draughts, and for the retardation of siltation of the reservoirs.
4. Checking the extension of sand dunes in the desert areas of Rajasthan and along
coastal tracts.
5. Increasing substantially the forest/tree cover in the country through massive
afforestation and social forestry programs, especially on all denuded, degraded and
unproductive land areas.
6. Meeting the requirements of fuel wood, fodder, minor forest produce and small
timber of the rural and tribal population.
7. Increasing the productivity of the forests to meet the essential national needs.
8. Encouraging efficient utilization of forest produce and maximizing substitution of
wood.
9. Creating a massive people's movement with the involvement of women for achieving
the above objectives and to minimize pressure on the existing forests.
It is noted from the outlines of the National Forest Policy 1988 that there is now a greater
emphasis on the expansion, conservation and preservation of the forests and ecology.
2.5.2 The National Environmental Policy
Although since long there was a concern for the environmental management in the
country as evident from the various Policies and Legislation the lead was given in the Sixth Plan
when a Chapter on 'Environment and Development' was included in the Plan document. The
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
11/61
Standard Operating Procedure for Pharmaceutical Industry
8
Chapter laying emphasis on the problems of environmental degradation provided guidelines to
the administrators for formulating and implementing the development programs incorporating
environmental concerns and laying down the institutional arrangements for environmental
management, administration and protection. The Eighth Plan on the basis of the overview of the
environmental and forest scenario identified the eight major tasks to meet the challenge of
environmental degradation.To complement the Constitutional sanctions, outlines earlier, MoEF in 1992 brought out
a Policy Statement for Abatement of Pollution and the National Conservation Strategy and
Policy Statement on Environment and Development which provides instruments in the form of
legislation and regulation, fiscal incentives, voluntary agreements, educational programs and
information campaigns for preventing, controlling and reducing environmental pollution. The
overall objective of the Policy was to integrate environmental considerations into decision
making at all levels and to achieve this, the following specific steps were identified.
1. Prevent pollution at source.
2. Encourage, develop and apply the best available practical solutions.
3. Ensure that polluter pays for the pollution control arrangements.4. Focus protection on heavily polluted areas and river stretches.
5. Involve public in decision making.
6. Increase the safety of industrial operations.
The MoEF issued the Environmental Action Programme in 1993 with the objective of
integrating the environmental concerns into the process of development. The various issues
addressed were reducing pollution at source, assistance for adaptation of the best available and
practicable technologies, mass based standards, fiscal measures, environmental audit,
environmental statistics, and public participation.
The National Conservation Strategy and Policy Statement on Environment and
Development, 1992 formulated with a view to reinforcing traditional ethos and to building up aconservation society living in harmony with nature and making efficient use of the resources
guided by the best available scientific and technical knowledge aimed at the following.
1. Ensuring sustainable and equitable use of the resources for meeting the basic needs of
the present and future generations without causing damage to the environment.
2. Preventing and controlling the future deterioration of the life support systems.
3. Taking steps for restoration of ecologically degraded areas and for environmental
improvement in the rural and urban settlements.
4. Ensuring that the developmental projects are correctly cited with least adverse
environmental consequences.
5. Conserving and protecting the coastal areas and marine eco-systems.
6. Protecting the scenic landscapes, areas of geomorphological significance, unique and
representative bio-mass and eco-systems and wild life habitats, heritage sites/structures and
areas of cultural heritage/importance.
For achieving the above the following actions were envisaged in the Policy.
1. Environmental impact assessment of all the developmental projects right from the
planning stage and integrating it with their cost-benefit considerations.
2. Compulsory prior environmental clearance of all projects above a certain size and for
those proposed to be constructed in ecologically sensitive and fragile areas.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
12/61
Standard Operating Procedure for Pharmaceutical Industry
9
3. Incorporation of environmental safeguards and protection measures in policies, planning,
site selection, choice of technology and implementation of the developmental projects,
i.e., industries, mining and mineral processing, forestry and human settlements.
4. Encouraging research and developmental activities, adaptation of environmentally
compatible technologies, and to promote application of the modern tools of science and
technology for conservation, bridging of large gaps in supply and demand as well ascontrolling and monitoring of the natural resources.
5. Encouraging public participation in environmental improvement programs and integrating
the environmental concerns in planning and implementation of the developmental
programs.
6. Creating environmental consciousness through education and mass awareness programs.
7. Aiming at the modernization of the process of demand unleashed by the development
process itself by taking measures to recycle waste materials and natural resources,
conserving energy and the use of the natural resources in the industrial products by
measures like wood substitution and generally trying to reach moderation in life style
consistent with the sustainable development and the human dignity.8. Developing appropriate organizational structure and a pool of professional manpower to
serve as the cadre for environmental management services.
9. Efficiently implementing the various environmental laws and regulations for
environmental protection through creation or strengthening of requisite enforcement
machinery.
It is evident that the Policy directives mean effective protection and management of
environment in all the developmental and industrial activities while keeping the goal of
sustainable development in view.
2.5.3 The National Industrial Policy
The New Industrial Policy, 1991 was formulated to provide an impetus to the pace of
industrialization in the country. This resulted in abolition of all industrial licensing for all the
industries except some specified industrial sectors. The Policy addresses the environmental
concerns along with objectives of sustainable development and states:
The major objectives of the new industrial policy package will be to build on the gains
already made, correct the distortions or weaknesses that my have crept in, maintain sustained
growth in productivity and gainful employment and attain international competitiveness. The
pursuit of these objectives will be tempered by the need to preserve the environment and ensure
the efficient use of available resources.
The New Industrial Policy lays stress on the following for the sustained development and
growth of the industry in the country.
1. Substantial reduction in the scope of industrial licensing.
2. Simplification of procedures, rules and regulations.
3. Reforms in the Monopoly and Restrictive Trade Practices Act.
4. Reduction of the areas reserved exclusively for the public sector.
5. Disinvestment of selected public sector enterprises.
6. Enhancing limits of foreign equity participation in domestic industrial undertakings.
7. Liberalization of trade and exchange rate policies.
8. Rationalization and reduction of customs and excise duties.9. Extension of the scope of modified value added tax (MODVAT).
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
13/61
Standard Operating Procedure for Pharmaceutical Industry
10
2.5.4 National Health Policy - 2002
A National Health Policy was last formulated in 1983, with the following noteworthy
initiatives:
i. A phased, time-bound programme for setting up a well-dispersed network of
comprehensive primary health care services, designed in the context that
elementary health problems can be resolved by the people themselves;
ii. Intermediation through Health volunteers having appropriate knowledge, simple
skills and requisite technologies;
iii. An integrated net-work of evenly spread speciality and super-speciality services;
encouragement of such facilities through private investments for patients who can
pay, so that the draw on the Governments facilities is limited to those entitled to
free use.
NHP-1983, in a spirit of optimistic empathy for the health needs of the people,
particularly the poor and under-privileged, had hoped to provide Health for All by the year
2000 AD, though in retrospect, it was observed that the financial resources and public health
administrative capacity which it was possible to marshal, was far short of that necessary to
achieve such an ambitious and holistic goal. Against this backdrop, the recommendations of
NHP-2002 make an attempt to maximize the broad-based availability of health services to the
citizenry of the country on the basis of realistic considerations of capacity.
The main objective of this policy is to achieve an acceptable standard of good health
amongst the general population of the country. The approach would be to increase access to the
decentralized public health system by establishing new infrastructure in deficient areas, and by
upgrading the infrastructure in the existing institutions.
2.5.5 The Pharma Policy 2002:
Any analysis of the recently announced Pharmaceutical Policy need to take into accountits role in ensuring the welfare of all the stakeholders that the stated Policy will affect in future
years. That includes the patients, who should be the ultimate beneficiaries, the Country and its
economic well being and the Indian Pharmaceutical Industry.
It is significant that the National Health Policy-2001 was announced a few months
earlier to the Pharmaceutical Policy-2002. One would have expected that the National Health
Policy would have devoted a section on the role of the Pharmaceutical Industry in providing
healthcare to the millions of Indians who have to have drugs as a basic need. In fact, the drugs
component of healthcare is higher in developing countries than in the developed World, since
due to the very slow improvements in public health measures witnessed in these countries, use
of drugs constitutes the most cost-effective approach to health care. And yet, there are hardlyany serious references in the National Health Policy on the role of drugs in reducing morbidity
and mortality, resulting from preventable diseases. Ideally, the two policies should have been
dovetailed, since their objectives have a high degree of commonality. For example, while
discussing and quantifying the goals and targets to be achieved in health, nutrition and disease
areas during the coming decade and a half, there is no analysis in the Health Policy of the
strategies to be adopted by the Pharmaceutical Industry to achieve those targets.
A plethora of new challenges face the Indian Pharmaceutical industry in the wake of
Indias commitment under the GATT and WTO, of which TRIPS is the most relevant part
affecting the industry. And it is in this context the present policy document is evaluated.
According to the Policy, on the licensing front, all shackles are being removed for all sectors of
the industry, reservations for the Public and Small Scale sectors have been abolished, and nominimum or maximum production levels have been prescribed, automatic approvals for import
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
14/61
Standard Operating Procedure for Pharmaceutical Industry
11
of technology for bulk drugs allowed and foreign investments even up to 100% equity
permitted.
2.6 REGULATORY CONCERNS ONNUTRACEUTICALS:
The class of products christened 'Nutraceuticals' had a relatively late entry into the
Indian Healthcare scene, even though diverse preparations originating from Indian Systems of
Medicine (ISM), notably Ayurveda have been marketed by several Companies, mostly as healthrejuvenators for decades. The approval for marketing these products are granted by State
Governments' Regulatory Agencies under the advise of experts in ISM.
The general principle adopted is that the constituents of the preparation should have been
mentioned as therapeutically useful in one or more of classical texts of ISM or in published
Pharmacopoeias. In such cases no additional clinical validation of their safety or efficacy is
required to be provided. The products are marketed as ISM drugs under the OTC category. To
encourage the revival and promotion of such products, the Government of India has provided
incentives in the form of tax benefits, and relief from administered prices, in addition to much
less stringent licensing or regulatory controls and standards.
The confusion not only among the regulatory agencies but also among the consumersincluding the medical profession as well as the patients arise out of the lack of clarity in defining
the precise nature, function and utility of these products as well as ambiguities with regard to
their safety and efficacy.
2.6.1 Mashelkar Committee Recommendations
India has specific Food Laws, of which only the Prevention of Food Adulteration (PFA)
comes under the purview of the Drugs & Cosmetics Act. Certain types of Nutraceuticals, which
fall under "Patent & Proprietary Medicines", which may or may not claim therapeutic properties
and Cosmetics, which have no therapeutic utility, are included under the Drugs & Cosmetics
Act. Even though there have been earlier recommendations by Committees constituted by the
Director General of Health Services (DGHS) and the Department of ISM & H of the Ministry ofHealth in 2000 and 2002 respectively, no decisions have been taken so far on their
implementation by the Government.
The processes of manufacture include extraction and fractionation, fermentation using
product-specific micro organisms and chemical synthesis. Even the same dietary supplement
manufactured by different manufacturers do not often meet the same standards and
specifications Thus it is obvious that evolving a uniform standard for the Dietary Supplement of
identical composition whether classified under the Food or Drug category is not easy.
Considering all these issues and taking into account the various earlier recommendations
during the last five years by different agencies on the subject, it was considered prudent to
recommend a regulatory system to streamline the activities of the Nutraceuticals Industrythrough appropriate legislations under the Drugs & Cosmetics Act or under the Food Act,
prevailing in the Country. The following recommendations when implemented will ensure that
the Industry will provide quality products manufactured under Good Manufacturing practices
and supported by adequate and sound evidence for their safety and efficacy.
1) All Nutraceuticals in the market or to be marketed to be classified as either Dietary (Food)
Supplements or as Drugs as defined under the Food Acts or the Drugs & Cosmetics Act.
2) Food Supplements, which do not have on their labels and /or are not promoted as having
therapeutic properties should be regulated under Food Laws, which need to be amended if
necessary to include them.
3) Products which claim to have utility as prophylactics, diagnostics or therapeutic agentsshould be considered as Drugs and would come under the purview of the Rules & regulations
under the Drugs & Cosmetics Act.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
15/61
Standard Operating Procedure for Pharmaceutical Industry
12
4) Whether they should be under Schedule H, Schedule K or under a new category of OTC
drugs is to be determined by their safety profiles and track record of use.
5) In both cases, adequate evidence consistent with the claims made should be provided to
establish their safety and efficacy in humans.
6) If retrospective data is not adequate, prospective studies should be carried out.
7) All products regardless of the categorization should meet minimum current GoodManufacturing Standards (cGMPs).
8) The labels should have list of contents, their composition, warnings on safety and possible
adverse reactions and shelf life where relevant.
2.7 RELEVANT INSTITUTIONS
Five departments are directly involved in the protection of environment due to Pharma
Industries and quarrying activity in the state, including the Ministry of Environment and Forest,
Govt. of India; The Department of Forests, Ecology and Environment, Govt. of Karnataka; and
Karnataka State Pollution Control Board
2.7.1 Ministry of Environment and Forest, Government of India
Ministry of Environment and Forest (MoEF) is the nodal agency at national level, in the
administrative structure for environmental protection and forest conservation. MoEF is assisted
by the Central Pollution Control Board (CPCB), a statutory authority at the central level in
executing responsibilities of prevention and control of pollution. Implementation of relevant
Acts and Rules and policy issues at the State level is overseen by the State Pollution Control
Boards (SPCB) and the State Department of Environment and Forest (DOEF). The governing
Acts and Rules are: Environment Protection Act-1986, Forest Conservation Act-1980 and rules
there under.
2.7.2 Department of Ecology and Environment, Government of Karnataka
Department of Ecology and Environment (DEE) is the state nodal regulating agency
responsible for environmental management of the state and can exercise promotional and
regulatory functions in pharma sector under the Air, Water and Environment Protection and
Forest Conservation Acts. The department also houses the State Environmental Clearance
Committee (SECC) which gives clearances to mining projects (major minerals) with lease area
less than 5 ha and mining projects (minor minerals) above 0.5 ha. The applications seeking
environmental clearances as per the EIA notifications are routed through DEE.
2.7.3 Karnataka State Pollution Control Board
KSPCB has regulatory and enforcement responsibilities with respect to air, water
pollution control and hazardous waste management in pharmaceutical under the Water(Prevention & Control of Pollution) Act, 1974, the Air (Prevention & Control of Pollution) Act,
1981 and rules there under, the Environment Impact Assessment Notification, 1994 & 1997 and
Hazardous Waste (Management & Handling) Rules, 1989 & amendments rules 2000. KSPCB
is responsible for conducting public hearing under Environmental Impact Assessment (EIA)
2.8 GUIDELINESSET BY KARNATAKASTATE POLLUTION CONTROL BOARD FOR SETTING
UP PHARMACEUTICALINDUSTRIES
1. The factory shall segregate the waste streams as biodegradable, non-biodegradable,
and inorganic streams etc., based on their characteristics and adopt appropriate methods of their
treatment and disposal.
2. A state of the art effluent treatment system shall be installed to treat the effluents tothe standards stipulated. The treatment of effluents shall ensure that the effluents are free from
toxic and hazardous effects.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
16/61
Standard Operating Procedure for Pharmaceutical Industry
13
3. Transportation .of toxic effluent from one stage to another, only for the sake of
disposal by dilution is prohibited.
4. The discharge of effluents into streams, rivers or surface water bodies is strictly
prohibited
5. The treated effluent conforming to stipulated standards shall be used on land for
agriculture. The factory shall own/acquire sufficient area of land for this purpose. Theapplication of effluent shall be controlled in such a manner as not to cause either flooding of
land or underground water pollution. Before allowing the use of treated effluent for irrigation,
the State Pollution Control Board shall ensure that the factory submits a report on geophysical
characteristics and assimilation capacity of land and suitability of effluents for agriculture
through recognized institutions. Adequate number of observation bores/test wells shall be
proved by the factory in and around the effluent irrigated area to monitor ground water quality.
The factory shall get the soil, leachate and ground water in the area analyzed at regular intervals
for parameters based on raw materials used and characteristics of effluent discharged to verify
the fate and effect of any persistent chemical.
6. Boilers, Diesel generating sets etc., shall be provided with chimneys of prescribed
height.7. The general exhaust from different sections shall be collected, and scrubbed to
control emissions. The reactor emissions shall be scrubbed to control emission of different
gases/vapours/fumes.
8. All solvent tanks located above ground level shall be blanketed with Nitrogen, there
by preventing any solvent evaporation and consequently minimizing odorous emissions.
9. State of art incinerator shall be provided wherever feasible to incinerate all
combustible effluents, solids, gases, toxic substances etc. The incinerator shall be fitted with a
chimney of prescribed height and scrubbers to clean the flue gases.
10. The factory shall ensure that the noise levels are within the stipulated limits and the
factory shall conduct periodic monitoring of noise levels at designated location at specified
intervals.11. Solid waste and sludge generated in the factory shall be collected, treated and
disposed of in a scientific manner so as not to cause environmeta1 pollution.
12. The factory shall install water maters to measure the water consumed for different
purposes as per the Water (Prevention and Control of Pollution) Cess Act, 1977, as amended,
and pay water cess.
13. The factory shall submit an Environmental statement Report for the financial year
ending the 31" March in the prescribed form to the State Pollution Control Board on or before
the 15th day of September every year.
14. The factory shall comply with the provisions of the:
i Hazardous wastes (Management and Handling), Rules, 1989.ii Manufacture, Storage and Import of Hazardous Chemicals Rules, .1989.
iii Public liability insurance Act and Rules, 1991
as amended from time to time, if applicable
15. All tanks used for the collection and treatment of effluents shall be made impervious
by providing adequate cement concrete/stone masonry/stone slab lining with leak-proof joints at
the bottom and sides. 1 observation bores with pipes shall be provided around such tanks and
monitored for leakage.
16. The factory shall upgrade the pollution control systems as and when new
technologies become available.
17. The factory shall ensure continuous and effective operation and maintenance of
pollution control systems by employing qualified Environmental Engineers/Scientists.18. The factory shall ensure continuous and uninterrupted power supply to see that the
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
17/61
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
18/61
Standard Operating Procedure for Pharmaceutical Industry
15
3 RESPONSIBILITIES OF THE PHARMACEUTICAL AUTHORITIES
3.1 APPROVALS
Approval for setting up Pharmaceutical Industries includes:
1 Should obtain the Environmental Clearance Certificate as per
Environmental Impact Assessment Notification, 1994 and its
amendments from the Ministry of Environment and Forests, GoI. The
application seeking environmental clearance (Schedule II of EIA
Notification) should be routed through Department of Forest, Ecology and
Environment for consideration after mandatory public hearing.
2 All the entrepreneurs before establishing an industry have to obtain consent for
establishment.
3 Any person who is likely to establish or take any steps to establish any Industrial Plant or
process or any treatment and disposal system or any extension or addition which is likely to
discharge sewage or trade effluent into any stream or well or sewer or on land has to obtain
consent of the Board.
4 Similarly any person who is likely to establish or operate any industrial plant in any air
pollution control area (Entire Karnataka has been declared as air pollution control area) is
not permitted to discharge or cause or discharges the emission of any air pollutant in excess
of the standards laid down by the State Board. These emissions shall be with prior consent
of the State Board.
3.2 RESPONSIBILITIES
Should comply with the consent conditions laid down by State Pollution Control Board
Should maintain relevant log books for daily water consumption, raw material used and
products manufactured, energy use and consumption, hazardous and solid wastegenerated, waste water generated, air emissions, etc.
Should submit yearly Environmental Statement to the concerned State Pollution
Control Board
Should submit yearly Water Cess Returns to the concerned State Pollution Control
Board
Should provide for wastewater treatment facility, air pollution control devices.
Should provide for safe drinking water and proper sanitation amenities for the workers
and also take into considerations the health and safety of the workers.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
19/61
Standard Operating Procedure for Pharmaceutical Industry
16
4 WATER AND AIR (PREVENTION & CONTROL OF POLLUTION) ACTS
The Water (Prevention & Control of Pollution) Act is an act to provide for prevention of
control of water pollution and maintaining or restoring of wholesomeness of water while, the
Air (Prevention & Control of Pollution) Act provides for the prevention, control and abatement
of air pollution. Under these two acts any new industry prior to commissioning should obtain
consent of the concerned State Pollution Control Board to establish and to operate.
4.1 CONSENT PROCEDURE
All new establishments like industries, water and wastewater treatment
systems, sewage treatment systems are required to obtain Consent for
Establishment and subsequently obtain Consent for Operation under the Air
and Water Acts. All the consent applications received will be subject to technical
evaluation and conditions imposed to protect the environment. Application Form I
and Form XIII, under the Air and Water Act, respectively, to be filled by the
applicant along with the consent fee and relevant documents. Pass Book system has
been introduced for renewal of consents.Depending upon the industries varying in pollution potential (red, orange, and green) and
capital investment (small scale, medium scale, and large scale) the consent fees varies.
The industries under large scale and medium scale RED category are required to obtain
consent every year.
Medium scale ORANGE and GREEN category industries are required to obtain consent
every year with an option for once in two years by paying two years fee.
Small scale RED, ORANGE and GREEN category have to obtain consent every year
with an option of once in three years by paying three year fee.
Tiny industries have to renew consent once in ten years by paying one year consent fee.
See Annexure II for Consent fee, frequency of consent application and the periodicity ofmonitoring based on the classification of industries.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
20/61
Standard Operating Procedure for Pharmaceutical Industry
17
5 WATER (PREVENTION & CONTROL OF POLLUTION)
CESS ACT
The purpose of Water (Prevention & Control of Pollution) Cess Act is levy and collect
cess on water consumed by 16 categories of industries specified in the schedule I of the act and
also by local bodies with a view to augment the resources of the Central and State PollutionControl Boards. Water cess is levied based on the water consumed for domestic and specified
industry. Cess is calculated on rate specified in Schedule II of the Act for different water users.
As per section 4 of the act the concerned industries are required to install standard water meters
at such places as may be required by the concerned authority for measuring and recording the
quantity of water consumed by the industry. The industry consuming water shall furnish the
cess returns in the prescribed form on or before 5thof every month to the Member Secretary of
the State Pollution Control Board. The authority assesses the returns filed after due verification
and amount payable is intimated to the user, which should be paid by demand draft by the user.
If the industry complies with the regulation by providing effluent treatment plant which
meets the standards prescribed in terms of quantity and quality, it is entitled to a rebate of 25%.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
21/61
Standard Operating Procedure for Pharmaceutical Industry
18
6 ENVIRONMENTAL IMPACT ASSESSMENT NOTIFICATION
Under the Environmental Impact Assessment Notification of 27/1/1994 and subsequent
amendments made on 04/05/1994, 10/04/1997, 27/1/2000, 13/12/2000, 01/08/2001 and
21/11/2001, powers are conferred on the Central Government by sub-section (1) and clause (v)
of sub-section (2) of section 3 of the Environment (Protection) Act, 1986 (29 of 1986) read with
clause (d) of sub-rule (3) of rule 5 of the Environment (Protection) Rules, 1986. Any expansion
or modernization of any activity (if pollution load is to exceed the existing one), or new project
listed in Schedule I to this notification, should be accorded environmental clearance by the
Central Government in accordance with the procedure specified in this notification.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
22/61
Standard Operating Procedure for Pharmaceutical Industry
19
Obtaining Environmental Clearance
nd is
No
Yes
Yes
Yes
No
Yes
No
No
Yes
Environmental Clearance issuedby Min. of Env. &. Forests
along with Stipulations
Recommended
by EAC
Public hearingarranged
Is the project
acceptableCan Issues be
resolved?
Investors advised
to look for
alternate site
Apply to Union
Min. of Env. &Forests in
prescribed
questionnaire
Apply to stateDOEn for
Environmental
Clearance
Does the Project
fall under schedule-
I of EIA
notification
Apply also
to CCF in
case of
forest la
involved.SPCB issues
NOC
RejectCan Issues be resolved
Submits Project questionnaire to
concerned SPCB
Investor
Is the project
site acceptable
Is the informationprovided adequate
Review by
Environmental Appraisal
Committee of the Min.
of Env. &. Forests
Initial scrutiny by staff of
Min. of Env.&.Forests
Submission of the project to the Min. of Env. &. Forestsalong with all documents listed at Part I of the handbook
Scoping by investor
Yes
No
Reject
Prepare comprehensive
EIA or any specific
study suggested by the
committee
Is site
acceptableNo
EAC Members
undertake site
visits
Is there a
public outcry
against the
project
Is the Environmental
Management Plan satisfactory
Review by SPCB
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
23/61
Standard Operating Procedure for Pharmaceutical Industry
20
7 ENVIRONMENTAL STATEMENT PROCEDURES
Environmental Management in industries hitherto based on and off pipe waste treatment,
is now based on the emerging philosophy of waste prevention and reduction. In order
to prevent or reduce waste generation, one needs to examine the production processes,to identify the origins of wastes, the operational problems associated with the
process and the areas requiring improvement. As per the notification issued by the
Ministry of Environment & Forest, Government of India on 13thMarch, 1992
(amended vide notification no. GSR 386 (E) dtd. 22.04.1993) under the
Environment (Protection) Act, 1986, all those carrying on an industry, operation or process
requiring consent to operate under section 25 of the Water (Prevention & Control of Pollution)
Act, 1974 and / or under section 21 of the Air (Prevention & Control of Pollution) Act, 1981
and/ or authorization issued under the Hazardous Waste (Management & Handling) Rules, 1989
and the Environment (Protection) Act, 1986 are required to submit the environmental statement
for every financial year ending 31stMarch in the prescribed form [Form V] to the concerned
State Pollution Control Boards on or before 30thday of September every year beginning 1993.Non-compliance with this mandatory requirement amounts to violation of the Environment
(Protection) Act, 1986.
7.1 CONTENTS OF ENVIRONMENTALSTATEMENT
A statement prepared by the industry shall include the following;
a. A description of the companys activities at site considered
b. An assessment of all the significant environmental issues relevant to there
activities
c. A summary of the figures on energy consumption, water consumption, raw
materials consumption, pollutant emissions, waste generation and othersignificant environmental aspects.
d. The industrys environmental policy objectives and targets
e. Details of the programme to be followed and the environmental management
system.
Environmental Statement helps industry to take a comprehensive role at their industrial
operations and facilities, understandings of material flows and focus on areas where waste
reduction and consequently saving input costs, if possible. Environmental Statement is to be
prepared by every industry by filling up one Environmental Statement Form V (enclosed vide
Annexure ) supplied by Pollution Control Board.
For the preparation of Environmental Statement, log book need to be maintained by the pharmaauthorities in their premises which would make the statement summarising easier. The log book
list is provide below
a. Water log book
b. Raw Material log book
c. Energy log book
d. Pollutant log book
e. Hazardous log book
The day to day summary from the log book can be summarised on monthly basis. A sample log
book is provided in Annexures.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
24/61
Standard Operating Procedure for Pharmaceutical Industry
21
8 ENVIRONMENTAL AUDITING
Environmental Audit has become a step to comply with the requirement to furnish the
Environmental Statement, though the importance of environmental audit lies in achieving
increased productivity and reduced waste generation. Auditing in general is a methodical
examination involving analysis, tests and confirmation of local procedures and practices whose
goal is verify whether they comply with legal requirements, internal polices and accepted
practices. Auditing differs from assessment in that it requires collection and documentation of
competent and sufficient evidence rather than an opinion based primarily on professional
judgement.
Environmental Audit is a technique being introduced for integrating
the interest of the industry and the environment so that there could be
mutually supportive. This technique is basically a part of industrys
internal procedures to meet their responsibilities towards better
environment. Environment Auditing is a management tool comprising a
systematic documented periodic and objective evaluation of how well the
management systems are performing with the aim of: Waste preventive and reduction
Assessing compliance with regulatory requirements
Facilitating control of environmental practices by a companys management, and
Placing environmental information in the public domain.
Environmental Audit in India is different from that in developed countries and the
definition of International Chamber of Commerce (ICC) is accepted. ICC defines
Environmental Audit is It is a management tool comprising a systematic, documented, periodic
and objective evaluation of how well environmental organization, management and equipment
are performing with the aim of helping to safe guard the environment by:
Facilitating management control of environmental practices.
Assessing compliance with company policies, which would include meeting,
regulatory requirement.
Environmental Statement which is a part of the Environmental Audit.
Environment Policy means a statement of a companys overall aims and principles of
action with respect to the environment.
8.1 FEATURES OF A GOOD ENVIRONMENTALAUDIT
A good Environmental Auditdefines sources, quantities & types of waste generation
Collates information on unit operations, raw materials, products, water usage and
wastes and increases knowledge of the process.
Highlights process and poor management
Helps to set targets for waste reduction
Permits the development of effective waste management strategies.
Rises awareness in the workforce regarding the benefits of waste reduction
Helps to improve process efficiency
Enables legislative compliance & avoids litigation.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
25/61
Standard Operating Procedure for Pharmaceutical Industry
22
8.2 AUDIT PROCEDURE
A step-by-step methodology for Environmental Audit as recommended by the United
Nations Environment Programme and the United Nations Industrial Development Organisation
(UNIDO) is illustrated in figure 1.
Phase 1: Pre-AssessmentAUDIT PREPARATION
Step 1 Prepare and organise audit team and resources.
Step 2 Divide Process into unit operation
Step 3 Construct process flow diagram linking unit
operations
PROCESS OUTPUTS
Step 7 quantify products / by-products
Step 8 Account for waste water
Step 9 Account for gaseous emissions
Step 10 Account for offsite wastes
PROCESS INPUTS
Step 4 Determine inputs
Step 5 Record water usage
Step 6 Measure current levels of
waste reuse/recycling
DESERVE A MATERIAL BALANCE
Step 11 Assemble input and output Information
Step 12 Derive a preliminary material balance
Step 13 and 14 evaluate and refine material balance
IDENTIFY WASTE REDUCTION OPTIONS
Step 15 Identify obvious waste reduction measures
Step 16 target and characterize problem wastes
Step 17 Investigate the possibility of waste segregation
Step 18 Identify the long term waste reduction measures
EVALUATE WASTE REDUCTION OPTIONS
Step 19 Undertake environmental and economic
evaluation of waste reduction options, list viable
WASTE REDUCTION ACTION PLAN
Step 20 Design and implement a waste reduction
action plan to achieve improved process efficiency
Phase 3: Synthesis
Phase 2: Material Balance
Quick Reference Audit Guide
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
26/61
Standard Operating Procedure for Pharmaceutical Industry
23
9 ENVIRONMENTAL PERFORMANCE
VERIFICATION EXERCISE
The Pharma authority is required to seek Environmental Clearance from the Ministry of
Environment and Forest, GoI, for a new or proposed expansion / modernisation and submitEnvironmental Impact Assessment report while applying for Environmental Clearance. The
authorities are also required to submit yearly Water Cess Returns and Environmental
Statement to the concerned State Pollution Control Boards. As of now, though the
Environmental Impact Assessment report is submitted through the State Pollution Control
Board, there is no provision to link the EIA report with the Environmental Statement which is
submitted yearly. However, this is an important step which would not only give the yearly
compliance but also the status of the environment over a period of time.
In this chapter we are suggesting the following activities which would provide a rigorous
analysis of environmental statement submitted by the Pharma authorities and develop an
effective institutional arrangement for implementing Environmental Audit in the state.
Verification of Environmental Audit by the Regulatory Authorities
Verification of Environmental Audit by the Third Party
For the verification process the following steps are suggested:
Step 1: Verification of maintenance of Log Books
Step 2: Verification of maintenance of Yearly Resource Auditing Books
Step 3: Verification of compliance Consent Aspects
Step 4: Verification of Environmental Aspects
Step 5: Verification of Environmental Statement in line with the data provided with the data
submitted with Environmental Impact Assessment report.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
27/61
Standard Operating Procedure for Pharmaceutical Industry
24
10 TYPES, SOURCES AND NATURE OF POLLUTION FROM PHARMACEUTICAL
INDUSTRY
10.1 INTRODUCTION
This chapter dea1s with the current environmenta1 issues in the manufacturing processes
of the pharmaceutica1 (bulk and formulations) industries. The processes in the pharmaindustries vary from company to company and therefore, for burgeoning environmental
professionals it is necessary to have an accurate knowledge of general manufacturing process,
waste streams, available technology, and regulatory issues affecting the pharma industries. This
chapter helps in
Understanding the diverse nature of pharmaceutical processes, and their varied
operations for manufacturing, purifying, and packaging drug products.
Learn about the typical ingredients used to manufacture pharmaceutical products.
Discover how the diverse manufacturing processes, reactions, and hazardous materials
produce a wide range of chemical and biological wastes.
Become familiar with the treatment technologies the industry is using to manage wastesafter they are generated.
Identify the pollution prevention efforts that companies can use for cost containment in
the pharmaceutical industry.
It is impractical to list the exact interpretations for individua1 manufacturing situations;
therefore, when in doubt about the impact of a particular process, it is essential that you consult
with appropriate agencies, and legal in house experts.
10.2 PHARMACEUTICALMANUFACTURINGPROCESSES
The pharmaceutica1 manufacturing industry encompasses the manufacture, extraction,
process, purification, and packaging of chemica1 materia1s to be used as medication or have a
therapeutic va1ue for humans or anima1s. A broad range of products that include natura1
substances from plants or anima1s, metals, organics, and wholly inorganic materia1s
characterizes the industry. The industry is a1so characterized by diversity of processes and
plant sizes, as well as waste quantity and qua1ity.
Pharmaceutical production operations may be batch, semi-continuous, or continuous.
However, batch methods are the most common. Many of the processes encompassed are
proprietary, but the general processes are identified and describing the broad range of
manufacturing processes used in the pharmaceutica1 industries is Figure 1.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
28/61
Standard Operating Procedure for Pharmaceutical Industry
25
Figure 1: General manufacturing processes used in the pharmaceutica1 industries
Chemical substances Micro organic cultures
External cleaning
(Washing, dust removal)
Synthesis
Direct use(antibiotics in powder
form)
Syrups
drops
phials
Vegetable or animal tissues
ExtractionPharmacologically active
substance
Freeze drying
Fermentation
Capsules
Granules
Tablets
Pills
Proportioning
Ointments
SuppositoriesFreeze -dried
products
Mixing with solid
excipients
Pastes
Dilution in liquids
Powders
Packaging
Manufacturing in the industry can be characterized by four processes namely fermentation,extraction, chemical synthesis, and formulation and packaging.
Fermentation is usually a large-scale batch process and involves fermentation, or
controlled growth of specific micro organisms, in a reactor vessel to produce a desired
product. The desired product is then recovered from the fermentation broth using
solvent extraction, adsorption, precipitation and filtration, or ion exchange. Wastewater
streams generated from fermentation processes include discharges from reactor cleanings
and sterilizations, off-gas scrubber effluents, and occasional off-specification batches.
Solvents used in extracting the product from the broth in the recovery process may be
discharged into the sewers in the wastewater streams as well.
Extraction refers to the extraction and recovery of a small volume of desired productfrom naturally occurring sources such as plant roots and leaves, animal glands, and
parasitic fungi. Extraction operations are usually either batch or semi-continuous.
Wastewater discharges from extraction processes include spent raw materials, solvents
used in extractions, and spills and equipment wash waters.
Chemical synthesis, either through batch or continuous processes (usually batch), is the
most common method of preparing pharmaceuticals. Synthesis of pharmaceuticals
involves reaction of the appropriate raw materials and recovery of the desired product.
Effluents from synthesis operations are highly variable as are the processes by which
they are generated. Process solutions, vessel wash waters, filtrates, concentrates, spent
solvents, and scrubber effluents are all sources of wastewater. Pump seal water, spills,and cleaning wash waters are additional sources. Any of these sources may contain
significant concentrations of volatile organics.
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
29/61
Standard Operating Procedure for Pharmaceutical Industry
26
Mixing, compounding, and formulating operations involve preparation of the active
ingredients into a dosage form for consumer use. The primary sources of wastewater
from these processes are from equipment washings, scrubber effluents, and spills.
Although wastewater streams from all four processes have the potential to contain high organic
loadings, fermentation and synthesis operations usually generate larger volumes of wastewater,
and the wastewaters generated usually contain higher organic loadings. Thus, thepharmaceutical manufacturing industry discharges significant quantities of organic compounds
intheir raw wastewaters as the industry primarily uses organic compounds as raw materials or
solvents.
10.3 COMPOSITION OF PHARMACEUTICALPRODUCTS
To understand the treatment of wastewaters it is very important to know the composition of
wastewaters, which in turn depends on the products that are manufactured either in the bulk or
in the formulations industries. This section outlines the various dosage forms and their rough
compositions, which later express themselves as pollutants in wastewaters. Table 1 outlines
dosage forms of pharmaceutical products and composition.
Table 10.1:Dosage forms of pharmaceutical products and compositionDOSAGE FORM CONSTITUENTS & PROPERTIES
Liquid solutions
Aromatic waters Volatile solids and oils, water
Liquors or solutions Water, chemicals
Syrups Sweetener, solvent, medicinal agent
Elixirs Sweetened hydro alcoholic solution, may be medicated
Spirits, essences Alcohol, water, volatile substances
Tinctures Natural drugs, extracted with appropriate solvents
Colloidions Pyroxylin in ether, medicinal agent, castor oil, camphor
Liniments Oily or alcoholic solutions, suspensions
Mucilages Colloidal polymer solutions
Parenteral solution Sterile, pyrogen-free, isotonic, pH close to that ofblood; oily or aqueous suspension
Ophthalmic Sterile, isotonic, pH close to that of tears; viscosity
builder
Nasal Aqueous, isotonic, pH close to that of nasal fluid;
sprays or drops
Otic Glycerol based
Mouthwash, gargles Aqueous, antiseptic
Inhalations Administered with mechanical devices
Enemas, douches Aqueous solution or suspension, may include
medicinal agent
Liquid dispersionsSuspensions Powder suspended in water, alcohol, glycol, or an oil;
viscosity builder, wetting agents, preservatives
Emulsions, lotions Oil-in-water or water-in-oil
Gels, jellies, magma Viscous, colloidal dispersions
Semisolid and Plastic
Dispersions
Ointments Hydrocarbon (oil), absorptive water-washable or water-
soluble bases; emulsifying agents; glycol, medicating
agent
Pastes and cerates Ointments with high-dispersed solids or waxes,
respectively
Suppositories Theobroma oil, glycerinated gelatin, or polyethyleneglycol base plus medicinal agent
Solids
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
30/61
Standard Operating Procedure for Pharmaceutical Industry
27
Bulk powder Comminuted or blended, dissolved, or mixed with
water
Effervescent powder Comminuted or blended, dissolved in or mixed with
water
Dusting powder Contains adsorbents
Insufflation Insufflator propels medicated powder into body cavity
Lyophilized powders Reconstitution by pharmacist of unstable productCapsules Small-dose bulk powder enclosed in gelatin shell;
active ingredient plus diluent
Masses or molded solid
pills
Adhesive or binding agents facilitate compounding;
prepared by massing and piping
Trouches, lozenges,
pastilles
Prepared by piping and cutting or disk candy
technology; compounded with glycero-gelatin
Tablet triturates Small molded tablets intended for quick complete
dissolution (e.g., nitroglycerin)
Granules Particle size larger than powder
Compressed tablets Dissolved or mixed with water; great variety of shapes
and formulations
Pellets For prolonged actionCoated tablets Coating protective; slow release
10.4 COMPOSITION OF PHARMACEUTICALPROCESS WASTES
For a broad understanding of the treatment of wastewaters a typical pharmaceutical
process wastes is summarised below in Table 2.
Table 10.2: Typical pharmaceutical process wastes.
WASTE DESCRIPTION PROCESS ORIGIN COMPOSITION
Process liquors Organic synthesis Contaminated solvents
Spent fermentation broth Fermentation processes Contaminated waters
Spent natural product, rawmaterials Natural product, extractionprocesses Leaves, tissues
Spent aqueous solutions Solvent extraction processes Contaminated water
Leftover raw material,
containers
Unloading of materials into
process equipment
Bags, drums (fiber, plastic, metal),
plastic bottles
Scrubber water from pollution
control equipment
Dust or hazardous vapor
generating processes
Contaminated water
Volatile organic compounds Chemical storage tanks, drums Solvents
Off-spec or out-dated products Manufacturing operations Miscellaneous chemicals
Spills Manufacturing and lab
operations
Miscellaneous chemicals, mercury,
other metals
Wastewater Equipment cleaning, extractionresidues
Contaminated water, pheno-based
Spent solvents Solvent extraction or wash
practices
Contaminated solvents
Used production materials Manufacturing operations Filters, tubing, diatomaceous earth
Used chemical reagents R & D operations Miscellaneous chemicals, solvents,
acid/alkaline wastes, radioisotopes,
formaldehyde, photographic
chemicals, silver
Spent ethylene oxide Sterilization operations Ethylene oxide
Miscellaneous wastes Maintenance operations Waste lube oils, vacuum pump oils,
cleaning solvents, paint strippingwastes, leftover paints and
accessories, spent fluorescent lamps,
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
31/61
Standard Operating Procedure for Pharmaceutical Industry
28
trash
Used packaging material Packaging operations Plastic, wood, cardboard, foam
products
Infectious/medical wastes R & D, manufacturing
operations, off-spec products
Vials, biomass, blood products,
human animal specimens
Incinerator exhaust On-site incinerators Metals, oxides
Natural gas combustion products Steam boilers Carbon compounds, oxides ofnitrogen and sulfur, boiler
blowdown, cooling tower sludges,
and sediments
10.5 TREATMENTCONTROL TECHNOLOGIES
From the earlier discussion of pharmaceutical (bulk and formulations) manufacturing processes,
it is apparent that pharmaceutical manufacturing is costly and complex. As already mentioned,
there may be ten to fourteen stages in the manufacture of a single new chemical entity, each
involving many chemicals and generating several waste products. Moreover, the pharma
industry is heavily impacted by QA/QC regulations. Though there are many cleaner production
and waste minimisation options possible for recycling and reuse of some of material, concernsabout quality of the products may drive the industry to use end-of-the-pipe treatment
technologies rather than in-process systems. Table 3 lists treatment control technologies that
can be /have been employed by the pharmaceutical industry to treat process wastewaters.
Table 10.3:Summary of probable end-of-pipe treatment processes for pharmaceutical
wastewatersSR. NO TECHNOLOGY
1 Equalization
2 Neutralization
3 Primary treatment
Coarse settleable solids removal
Primary sedimentation
Primary chemical flocculation/ clarificationDissolved air flotation
4 Biological treatment
Activated sludge
Pure oxygen
Powdered activated carbon
Trickling filter
Aerated lagoon
Waste stabilization pond
Rotating biological contactor
Other biological treatment
5 Physical/chemical treatment
Thermal oxidationEvaporation
6 Additional treatment
Polishing ponds
Filtration
Multimedia
Activated carbon
Sand
Other polishing
Secondary chemical flocculation/
clarification Secondary neutralization
Chlorination
The pharma industries create many different types of waste streams; therefore, it is
impossible to list all the control technologies they use. The pharma industries use a wide variety
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
32/61
Standard Operating Procedure for Pharmaceutical Industry
29
of treatment processes: physical, chemical, biological, thermal, and stabilization. A brief
summary of the treatment processes available to the pharma industries is outlined here.
10.5.1 Physical Treatment Processes
Physical treatment processes are those using physical characteristics to effect a
separation or concentration in a waste stream. The processes are organized into four groupings:
gravity separation, phase change, dissolution, and size/adsorptive/ionic characteristics. Table 4presents the treatment technologies under each of these groupings.
Table 10.4:Physical treatment processes and technologies.
GRAVITY
SEPARATION
DISSOLUTION PHASE CHANGE SIZE/ ADSORPTIVE/
IONIC
CHARACTERISTICS
Sedimentation Soil washing/ flushing Evaporation Filtration
Centrifugation Chelation Air stripping Carbon adsorption
Flocculation Liquid/liquid
extraction
Steam stripping Ion exchange
Oil/waterseparation Supercritical solventextraction Distillation Electrodialysis
Dissolved air
flotation
Heavy media
separation
10.5.2 Chemical Treatment Processes
The chemical treatment processes are the most commonly used waste treatment practices. These
include:
pH adjustment for neutralization orprecipitation
Hydrolysis and photolysis
Oxidation and reduction
Ozonation
Hydrogen peroxide oxidation
Alkaline chlorination
Hypochlorite chlorination
Electrolyte oxidation
Chemical dechlorination
10.5.3 Biological Processes
Biological degradation is fast becoming a viable approach to waste management.
Originally, environmental engineers used biological degradation of hazardous organic
substances in the treatment of municipal wastewater, especially processes based on aerobic
bacteria or anaerobic bacteria. Aerobic biological treatment is a treatment technology
applicable to wastewaters containing biodegradable organic constituents and some nonmetallic
inorganic constituents including sulfides and cyanides. Anaerobic digestion is best suited to
wastes with moderate to high pH non-halogenated hydrocarbons, moderate to low organic
loadings, and low to zero biological oxygen demands. Some of the biological processes include:
Aerobic biological treatment
Activated sludge
Rotating biological contactors
Bioreclamation
-
7/22/2019 SOP Pharmaceutical Industries EMPRI 2005 12
33/61
Standard Operating Procedure for Pharmaceutical Industry
30
Anaerobic digestion White-rot fungus
10.5.4 Thermal Destruction Processes
Thermal destruction processes include several energy recovery processes, traditional
incineration processes, and several innovative thermal processes. These processes include:
Liquid injection incineration
Rotary kiln incineration
Fluidized bed incineration
Paralysis
Wet air oxidation
Industrial boilers
Industrial kilns (cement kiln,
aggregate, clay)
Blast furnaces (iron and steel)
Infrared incineration
Circulating bed combustor
Supercritical water oxidation
Advanced electric reactor
Molten Salt destruction
Molten glass
Plasma torch
You can incinerate any waste at some cost. Technical limits exist for specific
incineration technologies, but there are no technical limits on incineration for any waste type.
10.5.5 Fixation and Stabilization Processes
Fixation and stabilization involves immobilization of the toxic and hazardous
constituents in the waste. You can immobilize constituents by either changing the constituents
into insoluble forms, binding them in an immobile, insoluble matrix, and/ or binding them in a
matrix that minimizes the material surface exposed to solvent exposure. Often the immobilized
product has structural strength sufficient to help protect it from future fracturing and leaching.
Most of these processes are proprietary. They include:
Lime-based pozzolan processes
Portland cement pozzolan process
Sorption
Vitrification
Asphalt-based (thermoplastic) micro encapsulation
Polymerization
10.6 POLLUTION PREVENTION: BEST DEMONSTRATEDPRACTICES
Companies are moving away from compliance-driven activities, to
Pollution Prevention (PP)